Comments Due March 16 - Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs; Extension of Comment Period

March 9, 2021 — 

During October 2020, the FDA announced a public meeting, held on November 16, 2020, and requested public input on a potential revised approach for considering the human medical importance of antimicrobial new animal drugs when assessing and managing the antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. Specifically, the Agency requested comments on the potential revised process for ranking antimicrobials according to their relative importance in human medicine, on the potential criteria for their ranking, and on the resulting ranked list of antimicrobial drugs.

Submit either electronic or written comments by March 16, 2021, to ensure that the Agency considers your comments regarding this public meeting and request for comments.

To learn more and to submit comments, visit https://www.regulations.gov/document/FDA-2020-N-1736-0009.

View AASV's comments at https://www.regulations.gov/comment/FDA-2020-N-1736-0040.